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Abstract. The transforming growth factor-ß (TGF-ß) plays a
pivotal role in the pathobiology of human gliomas: during
carcinogenesis, it turns from a tumor suppressor to a tumor
promoter. The traditional Smad pathway and the more
recently discovered MAPK pathway are the most important
pathways for TGF-ß related intracellular signal transduction
mediating differential pathobiological effects. In this study, we
investigated the effects of TGF-ß2 and the TGF-ß2 antisense
phosphorothioate oligodeoxynucleotide (PTO) AS-11 on the
functionality of both the Smad and MAPK pathways in high-
grade gliomas. We aimed to correlate the imbalance between
the pathways with differences in the behaviour of high-grade
glioma cells. Gene and protein expression studies were used
to detect levels of members of the Smad and MAPK path-
ways under regulation of TGF-ß2 and AS-11. Proliferation and
migration assays were functional readouts for effects caused
by these regulating tools. Gene arrays were used to detect yet
unknown regulators of these functional effects. The Smad path-
way was functional in the tested cell lines. Exogenous TGF-ß2
inhibited proliferation but enhanced migration. Smad 2 mRNA
expression and activation were significantly reduced by
incubation with AS-11. K-ras was reduced both in gene arrays
and quPCR under treatment with AS-11, but there was no
influence of K-ras down-regulation on the activity of ERK.
Ubiquitination-related genes also were specifically down-
regulated with AS-11. Our results indicate the involvement of
K-ras in TGF-ß signaling in high-grade gliomas. ERK, which
is a member of the MAPK pathway, was not influenced and
seems to be activated through RAS independent cascades in
glioma. These results suggest that combined antagonization
of the TGF-ß and MAPK pathways might be a promising
approach for glioma therapy. An imbalance between these two
pathways might be responsible for TGF-ß switching to a tumor
promoter protein in high-grade gliomas.
Introduction
The transforming growth factor-ß (TGF-ß) is a multi-
functional ubiquitous polypeptide cytokine that initially was
named for its ability to induce transformation to a mesenchymal
phenotype in cultured epithelial cells (1). In healthy tissue,
but also low-grade epithelial tumors, TGF-ß induces growth
arrest and therefore is considered as a classical tumor sup-
pressor protein. In later stages of carcinogenesis, this effect
turns to the opposite with TGF-ß playing a pivotal role as an
autocrine stimulus of growth and dedifferentiation (2).
Besides these autocrine effects, various other, mainly
paracrine, functions emphasize the role of TGF-ß as a key
player in the pathobiology of malignomas: it is a highly
potent suppressor of immune reactions (3), an inductor of
angiogenesis (4) and a promoter of cell motility and
malignant invasive capacity (5; Arslan F, unpublished data).
Congruently, TGF-ß secretion is enhanced in various
malignant entities, such as malignant gliomas (6,7),
pancreatic carcinomas (8,9) and colorectal carcinomas (10-
12), turning the cytokine into a promising target for new
therapeutical approaches.
In human malignant gliomas, overexpression and secretion
of the TGF-ß2 isoform has been described as a hallmark of
its pathobiology (13). All three TGF-ß isoforms (-ß1, -ß2 and
-ß3) interact with the serine-threonine kinase type TGF-ß-
receptor (TGFß-R) types I and II. Commonly, mutations in
the TGF-ß signaling cascade are blamed for the switch from
tumor suppressive to tumor promoting effects.
Besides the traditional Smad pathway, which has been well
characterized as a TGF-ß signal transductor mediating mainly
anti-proliferative effects (14), a number of other intracellular
signaling cascades have been characterized. Yet, the mitogen-
activated protein kinase (MAPK) pathway as inductor of a
mesenchymal phenotype seems to be the most important of
these (15,16; Henis YI, Proceedings of the 1st German Work-
shop on TGF-ß, 2005). A dysbalance between the Smad and
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MAPK pathways with loss of anti-proliferative effects and
induction of dedifferentiation is commonly blamed for the
tumor promoting effects of TGF-ß on malignant cell types
(28), but is not well described for high-grade gliomas. Under-
standing the nature of these changes therefore seems to be
crucial for finding novel anti-neoplastic therapeutical strategies.
There are three different functional groups of Smad
proteins: receptor-regulated R-Smads (Smad 1, 2, 3, 5 and 8),
the co-receptor Smad (Co-Smad) 4 and the inhibitory I-Smads
(Smad 6 and 7) (14,17). Smad proteins are activated by
phosphorylation (14). Smad phosphorylation leads to nuclear
translocation, where Smad proteins can interact via the Smad
binding element (SBE) either in homotrimeric or heteromeric
complexes with other transcription factors to process their
target genes (18-20). Smads are known to mediate the anti-
proliferative effects of TGF-ß signaling, whereas mutations
either of the TGFß-R, the Smads themselves or downstream
effectors/cooperators are commonly believed to cause the lack
of growth inhibition after malignization of the cells (6,21,22).
The MAPK pathway involves ras, Raf and ERK1/2.
Initiating the signaling cascade, ras gets activated by phos-
phorylation of different effectors, among them the active
TGFß-R. Phosphorylated Ras (pRas) activates the down-stream
serine threonine kinase Raf, which triggers the phospho-
rylation of the extracellular signal-related kinase (ERK) (23).
Whilst a variety of cellular processes such as differentiation
and proliferation are regulated by the MAPK pathway (24),
mutations of the Ras gene have been described as pivotal in
the carcinogenesis of various tumors (25-27). In addition to
Smad pathway mutations, changes in the MAPK signaling
cascade are commonly connected to the promotion of invasion
by overexpression of extracellular matrix molecules and cyto-
skeletal rearrangement (28-30).
In this study, we investigated the effects of TGF-ß2 and
the specific antisense phosphorothioated oligodeoxynucleotide
(PTO) AS-11 (31) on both the Smad and the MAPK pathway
with the aim to correlate the imbalance between the pathways
with differences in the behaviour of high-grade glioma cells.
Materials and methods
Cell culture. Different types of glioma cell lines and primary
cultures were used for in vitro experiments. Human high-grade
glioma cell lines U87 and A172 were obtained from American
Type Culture Collection (Manassas, VA). The gliomas named
as ‘HTZ’ were primary tumor cell cultures derived from
surgical specimens of human high-grade gliomas (WHO
grade IV) as described before (32). All tumor cells were
maintained as standard monolayer cultures in tumor growth
medium at 37˚C, 5% CO2, 95% humidity in a standard tissue
culture incubator. Growth medium was comprised of Dulbecco's
modified Eagle's medium (DMEM; Invitrogen, Carlsbad,
CA) supplemented with 10% fetal calf serum (FCS).
Phosphorothioate oligodeoxynucleotides. We used the TGF-ß2
specific antisense-PTO AS-11 with the sequence 5'-GTA GTG
CAT TTT TTA AAA AA-3' (mRNA target region 171-190)
(Sigma-Genosys, Steinheim, Germany) (31). As control PTO,
we used AS-11m with 3 mismatch bases (sequence: 5'-GTA
ATG AAT GTT TTA AAA AA-3').
AS-11 specific suppression of TGF-ß2 secretion. Cells
(2.0x105 per well) were seeded in a 6-well plate and incubated
with 1 ml DMEM supplemented with 5% FCS. Fractions were
not treated or treated for 6 days with 1, 10, 15, and 20 μM of
AS-11, AS-11m. Media, including AS-11 and AS-11m
additions, were changed every 48 h. After 6 days, supernatants
were aspirated and a TGF-ß2 ELISA was performed.
Lipofectamine transfection was performed in parallel with the
same concentrations of oligonucleotide to evaluate the effect
of lipofectamine on transfection efficacy and cell toxicity.
Cell proliferation assay. Cells (2.5x105 per well) were seeded
in a 24-well plate and incubated with 1 ml DMEM supple-
mented with 5% FCS. Fractions were not treated or treated
with 10 ng/ml TGF-ß2 and 10 ng/ml bovine serum albumine
(BSA) as control, and cells were counted at days 2, 4, 6, 8
and 10. Media including the additions were changed at day 8.
Spheroid assay. Multicell tumor spheroids were initiated by
seeding 3-8x106 cells incubated in agar-coated wells in order
to inhibit adhesion. Mature spheroids with a mean diameter
of 200-250 μm were explanted to uncoated 96-well plates
containing no supplement, 10 ng/ml BSA as control, 10 ng/ml
TGF-ß2, and 10 and 15 μM AS-11 (Fig. 2). The dose of 10 ng/
ml TGF-ß2 was chosen from previous studies showing that
this concentration was as effective as higher concentrations
concerning induction of proliferation in high-grade glioma
cell lines (data not shown). Spheroids were allowed to migrate
for 5-7 days. The area covered by cells migrating away from
a spheroid was photographed and measured manually using
the greatest diameter. Assays were performed in triplicates
and repeated twice.
ELISA. For the quantitative determination of activated human
TGF-ß2 concentrations in cell culture supernatants, the
quantitative sandwich enzyme immunoassay technique was
used with a commercially available human TGF-ß2 specific
immunoassay kit (R&D Systems, Minneapolis, MN). The
minimum detectable dose of TGF-ß2 was less than 7.0 pg/ml.
The assay was performed in triplicates and as directed in the
manufacturer's instructions.
Western blot analysis. Cell extracts from cultured cells were
prepared by PhosphoSafe™ Extraction Reagent (EMD Bio-
sciences, San Diego, CA) following the manufacturer's
instructions. After extraction, equal amounts of samples (20 μg)
were boiled for 5 min with Laemmli sample buffer and loaded
directly into pre-poured Tris-HCl-glycine SDS-PAGE gels
along with pre-stained molecular weight standards (Bio-Rad
Laboratories, Palo Alto, CA). Electrophoresis was performed
in Tris/glycine/SDS running buffer (Bio-Rad Laboratories) at
125-150 V for a suitable migration period. Following transfer
to PVDF (polyvinylidene difluoride) membrane (Bio-Rad
Laboratories) at 120 mA constant current for 1-2 h, blots were
briefly washed in TBST (10 mM Tris, 150 mM NaCl, and
0.5% Tween-20, pH 8.0), and blocked for 1 h at RT in 5% non-
fat dry milk. Specific antibodies (PhosphoSmad 2: Calbiochem,
Laeufelfingen, Germany; Phospho-ERK1/2: R&D) were used
in concentrations as suggested by the manufacturers and
immunocomplexes were visualized using a horsedish peroxi-
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dase-conjugated antibody followed by chemiluminescence
reagent (Pierce Biotechnology, Rockford, IL) detection on
photographic film.
Quantitative PCR. Total RNA was extracted from glioma cells
with the RNA purification system RNeasy Mini Kit (Qiagen,
Hilden, Germany) following the manufacturer's instructions.
RNA concentration and purity was determined by measuring
optical density at wavelengths of 260 and 280 nm using a
standard spectrophotometer. First-strand cDNA generated from
1 μg of total RNA samples by using a reverse transcription
kit (Promega, Madison, WI) was used to amplify gene-specific
cDNAs from expressed genes.
To precisely quantify mRNA expression, a real-time PCR
system (ABI PRISM® 7000 Sequence Detection System, CA)
that measures nucleic acid molecules based on the detection
of a fluorescent reporter molecule (SYBR Green dye) was
used. Target-cDNA specific primers (Sigma-Genosys) were
established (sequences: Smad 2 forward, 5'-AGT ATT AAC
TCA GAT GGG ATC CCC TTC-3'; Smad 2 reverse, 5'-CTT
TAA TTG ATG AGA CCT CAA GTG CTG-3'; Smad 4
forward, TAG 5'-CTC CAG CTA TCA GTC TGT CAG C-3';
Smad 4 reverse, 5'-TCT GCA ATC GGC ATG GCT GGT
ATG AAGT AC-3'; K-ras forward, 5'-CCT GCT GAA AAT
GAC TGA AT-3'; K-ras reverse, 5'-ATA CAC AAA GAA
AGC CCT CC-3'). Annealing temperatures were optimized
for each primer pair using the following program: DNA poly-
merase activation at 95˚C for 5 min, denaturation at 95˚C for
45 sec, annealing at 57-60˚C for 1 min, extention at 72˚C for
45 sec with amplification for 30 cycles. RT-PCR products were
analyzed on a 1% agarose gel and visualized with ethidium
bromide staining. The housekeeping gene ß-actin was used as a
positive control to assess cDNA quality. Serial 2-fold dilutions
of cDNA were amplified to construct standard curves for
both the target gene and the endogenous reference (ß-actin).
Standard curves were used for extrapolation of expression
levels for the unknown samples based on their threshold cycle
(Ct) values. All amplifications of unknown samples were in
the linear range. For each reaction, melting curves were used
to verify the identity of the amplification products. The target
gene amount was divided by the housekeeping gene amount
to obtain a normalized target value. Each of the experimental
normalized values was divided by the normalized control
(untreated) sample value to generate the relative expression
levels in fold.
Gene arrays. U133 Plus 2.0 arrays (Affymetrix, Santa Clara,
USA) were used for hybridization following the protocol of the
manufacturer. For data analysis, NIH David 2.1 Beta analysis
software was used. To classify a gene as changed, a 2-fold
increase or decrease of expression in one of the fractions was
required. To meet the criteria of ‘specific effects’, expression
after treatment with AS-11 was compared to expression after
AS-11m treatment and the untreated control group. ‘Un-
specific effects’ were assumed if gene expression changed
compared to the untreated control group, whereas AS-11 and
AS-11m treated cells showed similar expression. For further
analysis, we used the ‘Functional Classification’ and the
‘KEGG pathway’ functions of the program. For ‘Functional
Classification’, ‘medium stringency’ was chosen as grouping
criterion.
Luciferase assay. A172 and HTZ-349 cells were seeded
2x105 per well. One fraction was stimulated with 10 ng/ml
TGF-ß2 for 24 h while another population remained untreated.
We used the Luciferase Assay Sytem (Promega) following
the manufacturer's protocol for transfection of the cells.
CAGA served as Smad-pathway specific reporter. Luciferase
activity was measured as baseline before treatment and after
stimulation and was compared to Renilla activity to calculate
the specific fold of induction after treatment. 
Results
Cultured glioma cells secrete TGF-ß2 in vitro. To select
suitable cell lines for further assays, we tested expression of
TGF-ß2 at the protein level in a series of human high-grade
glioma cell lines. In 8 out of 10 cell lines tested, we detected
measurable TGF-ß2 concentrations in the supernatants. For
the TGF-ß2 secreting lines, concentrations ranged between
110.46 pg/ml and 830.86 pg/ml (Table I).
Antisense-PTO AS-11 specifically suppresses TGF-ß2 protein.
To test the capability of the 20 oligomer TGF-ß2 specific
Antisense-PTO AS-11 to regulate TGF-ß2, we performed dose-
finding pre-assays with 4 cell lines (A172, HTZ-349, HTZ-417
and HTZ-419). We observed a nearly linear dose-dependent
suppression of TGF-ß2 concentrations in medium supernatants
(data shown for A172, Fig. 1A). The assays were performed
in parallel with lipofectamine-enhanced transfection. How-
ever, transfection efficacy was only slightly enhanced, and
lipofectamine was shown to be toxic on high-grade glioma
cells. Therefore, all further transfections were performed
without lipofectamine.
For further experiments, A172 and HTZ-349 were chosen
because of their growth and regulation patterns. Both were
incubated with the TGF-ß2 specific Antisense-PTO AS-11 and
AS-11m as mismatch control at a concentration of 15 μM.
AS-11 caused an average TGF-ß2 suppression of 36% in A172
cells, while AS-11m caused an unspecific average reduction
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Table I. TGF-ß2 concentrations as detected by ELISA in
supernatants of 10 high-grade glioma cell lines after 2 days
of incubation.a
–––––––––––––––––––––––––––––––––––––––––––––––––
Cell line TGF-ß2 ELISA (pg/ml)
–––––––––––––––––––––––––––––––––––––––––––––––––
U87 (ATTC) Below sensitivity
A172 (ATTC) 594.98±43.95
HTZ-190A 110.46±8.04
HTZ-222 119.39±2.63
HTZ-236 274.57±18.56
HTZ-324 Below sensitivity
HTZ-349 830.86±24.76
HTZ-417 121.88±4.34
HTZ-419 815.11±31.72
HTZ-421 223.41±9.05
–––––––––––––––––––––––––––––––––––––––––––––––––
aEight of the 10 cell lines produce measurable levels of TGF-ß2.
–––––––––––––––––––––––––––––––––––––––––––––––––
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of 11%. In HTZ-349 cells, TGF-ß2 secretion was suppressed
by an average of 26.9%, whereas AS-11m caused only 9.6%
suppression (Fig. 1B).
TGF-ß inhibits proliferation of A172 and HTZ-349 cells.
The Smad pathway is a TGF-ß induced mediator of anti-
proliferative effects (52). To investigate the effects of TGF-ß2
on the proliferation of HTZ-349 and A172 cells, we performed
a 10-day proliferation assay. TGF-ß2 had anti-proliferative
effects on both cell lines, with the most prominent decrease
of proliferation after 12 days of incubation. In A172 cells,
proliferation was decreased by 44% after 10 days in comparison
to untreated control, whereas BSA treated cells showed no
significant growth inhibition (data not shown). In HTZ-349
cells, proliferation decreased 32.0% for TGF-ß2 after 10 days.
TGF-ß1 had similar effects (Fig. 2A).
TGF-ß enhances migration of A172 and HTZ-349 spheroids,
and AS-11 reverts this effect. As inductor of a mesenchymal
cell type, MAPK pathway related effects have been described
to enhance also the migratory capacity of malignant cells
(58). A 4-day migration assay was performed with A172 and
HTZ-349 cell spheroids, testing the MAPK mediated TGF-ß2
induced migration of glioma cells. The most prominent impact
on migration was observed in the TGF-ß2 stimulated
population with migration increased by 15% in comparison to
the untreated control group. AS-11 treated cells showed a
dose-dependent decrease of migration (10 μM: 13.8%, 15 μM:
21.8%) in comparison to untreated controls (Fig. 2B). A172
cells showed similar results (data not shown).
AS-11 acts as specific antagonist of the TGF-ß2/Smad pathway.
We investigated mRNA expression levels of Smad 2 and
Smad 4 in A172 and HTZ-349 cells incubated for 6 days with
15 μM AS-11 and 15 μM AS-11m. Smad 2 mRNA levels
were down-regulated to 64% in AS-11 treated HTZ-349 cells,
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Figure 1. Dose-dependent suppression of TGF-ß2 as detected by ELISA in
supernatants of cell lines HTZ-349 and A172 after 6 days of incubation with
AS-11. The use of lipofectamine as an enhancer of transfection produces
similar transfection efficacies with enhanced toxicity. Transfection of the
mismatch control PTO AS-11m is not able to induce significant down-
regulation of TGF-ß2.
Figure 2. TGF-ß-dependent proliferation and migration (as tested with a
spheroid assay) of HTZ-349 cells. A172 showed similar effects in a less
pronounced manner. Stimulation with both isoforms of TGF-ß caused anti-
proliferative effects. Migration was significantly enhanced by exogenous
TGF-ß2. Antagonization of TGF-ß2 by AS-11 showed a dose-dependent
suppression of migration. Incubation with BSA as control protein mixture had
no impact on proliferation or migration.
Figure 3. (A), Regulation of Smad 2 and 4 as detected by quPCR in cells
incubated with AS-11 and AS-11m and an untreated control group (6 days).
The AS-11 treated group showed significantly lowered Smad 2 and elevated
Smad 4 levels (results shown for HTZ-349 cells, A172 cells showed analogous
results with lower significance). (B), Luciferase assay with A172 and HTZ-349
cells. Both cell lines are stimulated with 10 ng/ml TGF-ß2. The Smad-specific
reporter shows an increase of signal activity after TGF-ß2 stimulation. (C),
Regulation of K-ras as detected by quPCR in cells incubated with AS-11 and
AS-11m and an untreated control group (6 days). K-ras is significantly down-
regulated after incubation with AS-11, but not in AS-11m treated cells. (D),
Phosphorylation of Smad 2 and ERK 1/2 after treatment with TGF-ß2 and
AS-11. In Smad 2-Western, the AS-11 treated cell population clearly shows
the weakest, the TGF-ß2 stimulated group the strongest signal. There is little
difference in signal intensity between the AS-11m treated group and the
untreated control group. There is no regulation of ERK after treatment (results
shown for A172 cells, HTZ-349 cells showed similar results with lower
significance).
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compared to the untreated control. AS-11m had no effect on
Smad 2 mRNA levels. Smad 4 mRNA expression was
increased almost 2-fold in AS-11 treated cells. Cells incubated
with AS-11m showed less increased Smad 4 mRNA levels
(Fig. 3A).
To evaluate the extent of TGF-ß2 related signal trans-
duction at the protein level, and since Smad proteins are
activated by phosphorylation (14), we performed Western
blots for phosphorylated Smad 2 as one of the first steps of
the intracellular signaling cascade. AS-11 treated cells showed
the lowest amount of phosphorylated Smad 2 (Smad 2-P),
whereas in cells incubated with AS-11m, Smad 2-P was nearly
as prominent as in the untreated cell fraction. As expected,
TGF-ß2 stimulated cells clearly showed the highest amount
of phosphorylated Smad 2 (Fig. 3D).
To substantiate the functionality of the Smad pathway, we
performed a luciferase assay. Both HTZ-349 and A172 showed
an increase of luciferase activity after incubation of cells with
TGF-ß2 in comparison with the untreated control group
(Fig. 3B), which speaks for the functionality of the Smad
pathway in the tested cell lines.
Down-regulation of K-ras mRNA expression by AS-11: impact
on the MAPK pathway. A172 and HTZ-349 human malignant
glioma cells were treated with AS-11 at a concentration of
15 μM for 6 days. After harvesting, mRNA was isolated and
array chip hybridization was performed. In A172 cells (54676
genes on chip, 33627 detectable), 271 genes were specifically,
889 genes were non-specifically altered in their expression.
Of the specifically altered genes, 191 were down-regulated,
80 were upregulated. Forty-one genes were only expressed
under AS-11 treatment. In HTZ-349 cells (54676 genes on
chip, 28611 detectable), 73 genes were specifically, 3164 non-
specifically altered. Of the specifically altered genes, 39 were
down- and 34 were upregulated.
We used NIH David 2.1. analysis software for functional
clustering and pathway analysis of specifically altered gene
expression. For A172 cells, upregulated genes were clustered
in five functional groups: catabolism, ubiquitination/ligase
activity (Table II), serine-threonine kinase activity, mRNA-
splicing and processing and gene transcription/DNA-dependent
cellular metabolism. Prominently, K-ras was down-regulated
in A172 cells due to specific effects. There were no other
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Table II. Regulated ubiquitination-related genes in A172 cells after a 6-day incubation with AS-11 (specific effects).a
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Ubiquitination related gene Accession no. Known functions Refs.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Fring (ring finger and FYVE-like 228980_at Ubiquitination associated protein, caspase- (59,60)
domain containing 1) associated Smad-antagonism
Ring finger protein 14 201824_at Associated with the androgen receptor signaling (61,62)
pathway and with ubiquitin cycle and ubiquitin-
like-protein ligase activity
Ring finger protein 12 224047_at Acts as a negative coregulator for LIM (63,64)
homeodomain transcription factors
Zinc finger protein (C2H2 type) 277 1555193_a_at Regulation of transcription, DNA-dependent; (65)
transcription factor activity
Membrane-associated RING-CH 201737_s_at Deletions and mutations in this gene were (66)
protein VI (MARCH VI) detected in esophageal squamous cell
carcinoma (ESCC), suggesting that this protein
may be a potential tumor suppressor
Hypothetical protein FLJ14281 222850_s_at Chaperone activity; protein folding (67)
Ubiquitin protein ligase E3 component 226921_at Takes part in ligase activity; ubiquitin cycle; (68,69)
n-recognin 1 biquitin-protein ligase activity
Tetratricopeptide repeat domain 3 1569472_s_at Ubiquitin-protein ligase activity, (67,70)
exact biological mechanism unknown
Protein phosphatase 4, 225519_at Serine-threonine kinase implicated in (67,71)
regulatory subunit 2 microtubule organization at centrosomes
Ring finger protein (C3H2C3 type) 6 203403_s_at Part of protein ubiquitination, (67,72)
exact biological mechanism unknown
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aUbiquitination of Smad proteins is known to play an important role in the termination of TGF-ß intracellular signaling activity.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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specific effects on gene expression of the TGF-ß2 signaling
pathways, but due to unspecific effects, gene expression of
downstream Raf was down-regulated, whereas MEK was
upregulated also due to unspecific effects (Fig. 4).
To substantiate these results, we performed quPCR on
mRNA samples of both cell lines. In both, K-ras was down-
regulated significantly due to specific AS-11 effects. Unspecific
effects had only little influence on down-regulation of K-ras
(Fig. 3C).
Down-regulation of K-ras has no impact on ERK1/2. Since
ERK1/2 is a major downstream target of K-ras and a key
player in malignant transformation of human cancer cells
(33,34), we determined the state of phosphorylation of ERK1/2
by Western blot analysis as an indicator of ERK activation.
In contrast to Smad 2 phosphorylation, Antisense-PTO treat-
ment and stimulation by TGF-ß2 had no effect on phospho-
rylation of ERK (Fig. 3D).
Discussion
TGF-ß2 is known to be secreted by high-grade gliomas both
in vivo and in vitro (3,35,36) and induces a malignant pheno-
type (13). Imbalance between the Smad and MAPK path-
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Figure 4. Specific alterations caused by AS-11 in the TGF-ß related pathway after 6 days (NIH David 2.1). Ras was down-regulated in an assay which used
specific antisense oligonucleotides against TGF-ß2. There were no other measurable alterations of this pathway as detectable by gene array.
Figure 5. Possible alterations in the Smad- and MAPK pathways leading to
TGF-ß tumor promoter activity.
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ways may be responsible for the malignant transition of low-
grade to high-grade gliomas. In this study, antisense oligo-
nucleotides that selectively inhibit gene expression were used
as an approach to study the functional role of TGF-ß2 in
glioma cells. After uptake of AS-11 into the cells, which is
mediated by receptor-targeted endocytotis (37-39), we were
able to specifically suppress the TGF-ß2 secretion. Since
Antisense-PTOs have been repeatedly reported to cause effects
by non-specific interactions especially with proteins of the
serine-threonine receptor group (40-42), the impact of an AS-
11 control PTO, AS-11m, on Smad-dependent TGF-ß2 signal
transduction was evaluated, but only minor unspecific PTO-
related effects were found.
Our results demonstrate that the antisense approach to
inhibit TGF-ß2 expression influences both the Smad and
MAPK pathways. Smad 2 mRNA was significantly reduced
in the AS-11 treated cells, and Smad 2 was inactive in AS-11
treated glioma cells. Smad 2 transcription rates can be used
as medium-term indicators for Smad 2 activity, since trans-
cription of Smad 2 and Smad 4 is triggered by post-translational
modifications of the two proteins (44). Moreover, Smad 4
transcription was enhanced in the AS-11 treated fractions. This
seemingly paradoxical finding can be explained by Smad 4-
Ras interactions. Ras has been described as an inductor of
Smad 4 degradation by ubiquitination. In the presence of
activated Ras, Smad 4 half-life averages at 3 h, whereas
successful antagonization of Ras can prolong Smad 4 half-
life to 8 h (44). We have also detected specific down-
regulation of 10 ubiquitination-related genes with AS-11 in
A172 cells, as the ubiquitination of Smad proteins plays an
important role in the termination of TGF-ß intracellular
signaling activity (45,46).
Consistent with the reduced expression of Ras and
ubiquitination-related genes due to specific effects of AS-11,
we hypothesize that heightened Smad 4 mRNA levels
indicate a reduced Smad 4 degradation. This decreased
degradation consecutively might lead to higher Smad 4
transcription due to its dependence on post-transcriptional
modifications such as phosphorylation in a Smad 2-like
manner. Also gene expression patterns pointed to a reduced
Smad 4 degradation.
The second major TGF-ß intracellular signaling cascade,
the MAPK pathway, showed decreased activity in AS-11
treated glioma cells. We detected that the expression of K-ras,
a brain specific isoform of Ras and the most prominent onco-
gene of the MAPK pathway (25-27), was down-regulated
exclusively in the AS-11 treated populations of both cell lines.
Activation of the MAPK pathway by activated TGF-ß
receptor complexes including Ras isoforms has already been
described for several cell types (15,16). To the best of our
knowledge, this is the first evidence for an involvement of
K-ras in TGF-ß dependent signal transduction in malignant
glioma cells, although pathological ras-activity has already
been observed in glioma cells (47-49).
An imbalance between MAPK- and Smad-dependent
TGF-ß signaling might well be the cause for the change of
TGF-ß from tumor suppressor to tumor promoter (28). Loss
of function in Smad signaling such as nonsense mutations or
deletions of the Smad 2 and Smad 4 gene loci have been
described as pro-oncogenic for several tumor entities (50).
However, the majority of tumors retain a functional TGF-ß
signaling system, nevertheless refractory to its growth inhibitory
effects. Upregulation of the MAPK pathway during the course
of carcinogenesis was blamed for an imbalance of the TGF-ß
pathways (51,52). In this context, Ras is thought to play a
central role. Ras induces Smad 4 degradation by enhanced
ubiquitination and therefore suppresses the anti-proliferative
Smad-mediated effects (29). Hyperactivity of Ras therefore
might be a key to TGF-ß-related tumor progression.
Moreover, Ras leads, via activation of its downstream
substrates, to the enhanced transcription of extracellular
matrix proteins and to cytoskeletal rearrangement, favouring
invasion and migration of the malignant cells (15,29,30).
Considering this, down-regulation of K-ras might explain the
inhibition of migration with AS-11 in our assays.
It is important to mention that in this model of TGF-ß
induced carcinogenesis, the growth inhibitory effects of the
Smad pathway are not fully antagonized. Indeed, colon cancer
cells lacking the TGFß-R showed slight growth inhibition
after reintroduction of a functional receptor, but their invasive
and migrative capacity was strongly enhanced (52). These
findings are supported by our own data that demonstrated the
TGF-ß induced growth inhibition, but increased migration of
high-grade glioma cells.
It remains open at this point how the imbalance between
Smad- and MAPK-dependent signaling originates (Fig. 5),
but our results emphasize that ras hyperactivity can at least be
influenced by TGF-ß antagonization. Therefore, a sufficient
TGF-ß antagonization might be a promising approach to
partially reverse the imbalance of the Smad- and the MAPK-
cascades.
Hence, there was little specific effect on gene expression
of Ras-specific downstream targets. There was no effect either
by TGF-ß2, nor by PTO incubation, on the state of phospho-
rylation of ERK1/2 as an endpoint of the MAPK cascade.
Activated Ras leads to phosphorylation of the cytosolic
serine-threonine kinase Raf, which in turn activates the
mitogene-activated protein kinase (MEK), finally leading to
activation of ERK (52). Since activated ERK is not only an
activator of multiple transcription factors, but also affects
parts of the cytoskeleton and various phosphatases, it leads
to a more mesenchymal phenotype of the cell and is a pro-
migratory factor (54). In this context, ERK becomes important
in the course of carcinogenesis (55). In most publications,
hyperactivity of the ras-raf-MEK pathway, mainly in the
course of ras mutations, is blamed for increased ERK
activation (53). Our results indicate that ERK activation is
not dependent on the ras-raf-MEK cascade in glioma. This is
consistent with previous studies that demonstrated that ERKs
are activated through a PKC-raf-MEK-dependent, but ras-
independent cascade in high-grade gliomas (56,57). ERK
activation has been described as an inhibitor of Smad signaling
by blocking Smad translocation into the nucleus (29). It
therefore seems to be another key actor in the process of the
imbalance between Smad- and MAPK-dependent signaling.
Furthermore, recently it has been reported that the ERK
pathway regulates glioma cell proliferation, migration and
differentiation (58). A combined approach of TGF-ß and
MEK/ERK antagonization therefore seems to be a promising
step towards a coherent new therapy for high-grade gliomas.
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